Fluorescent 3-D imaging technique tracks disease models without surgery
A new rapid 3-D imaging system offers a non-invasive approach to accurately monitoring tumour development in adult zebrafish.
Animal testing is an essential step in developing new drugs for diseases. However, the process usually involves invasive procedures with animals that must be euthanized.
Researchers from Imperial College London and University College London (UCL) have now demonstrated a new way to study the progression of disease by adapting an imaging method called optical projection tomography (OPT).
The success of this MRC-funded collaboration means the scientists can now image and measure the growth of cancerous tumours and the associated development of growth-enabling blood vessels in live zebrafish.
This non-invasive method repeatedly images the same organisms, thereby reducing the number of animals used in testing. It is also able to yield high-resolution 3-D images at a fraction of the time and cost of other imaging techniques.
"The goal here is to visualise the progression of disease inside a live fish," said Professor Paul French, from the Department of Physics at Imperial, who led the development of OPT. Zebrafish develop cancer in a way similar to humans
"This technique has the advantage of being simple and robust," he added. "Unlike the other 3-D optical imaging techniques, it doesn't rely on focused light, so it is relatively gentle on the organism being imaged. This makes it particularly good for imaging live animals across long timescales."
Essential to tumour development is angiogenesis, the process by which tumours generate their own blood vessels to deliver the nutrients that enable growth. This process also facilitates the spread of tumours to other parts of the body, usually resulting in poor patient prognosis and death.
In a preliminary study, the OPT system was used to image zebrafish over time during tumour progression, allowing the researchers to measure tumour size and the amount of blood vessels within the tumour.
Being able to track the stages of disease progression in a living organism means the team could also use the technique to monitor the effects of new anti-cancer drugs that aim to reduce tumour size.
This approach uses genetic fluorescence labelling techniques, which allow internal organs to be visualised through their emission of different colour light. In the study, zebrafish whose blood vessels were labelled with a red fluorescent protein were bred with zebrafish that grew liver tumours labelled with a green fluorescent protein when given a chemical compound called doxycycline.
As the offspring of these fish have both genes, when imaged, their blood vessels fluoresce red and the liver tumour fluoresces green.
Paul Frankel, from the Division of Medicine at UCL, who led the cancer biology aspects of the project, said: "Zebrafish serve as animal models of liver cancer, developing a form of the disease genetically similar to human cancer tumours. This, as well as their small size, quick reproduction and transparency – which is necessary for OPT imaging – makes zebrafish an ideal organism to study using this technique."
Co-first author, Nicola Lockwood from the Division of Medicine at UCL said: "With the zebrafish model, we were able to directly visualise live progression of tumours within the context of a fully formed blood supply and immune system. This will be extremely important as we proceed to development of novel anti-cancer drugs."
The ability to perform studies over time allows researchers to assess disease progression in the same organism over spans of weeks to months. In one study the team repeatedly imaged zebrafish expressing red fluorescent blood vessels over a period of five months.
Such longitudinal studies will enable research into potential long-term side effects of drug treatments including adverse reactions and the development of drug resistance.
"It's well known that individuals can respond differently to the same drug treatment, therefore techniques such as ours could provide valuable information regarding disease progression and drug efficacy," said Professor French.
The team are currently combining OPT with other techniques, such as fluorescence lifetime imaging, to map cell signalling processes. This could be used to monitor cell death, making it potentially useful to test chemotherapy drugs and identifying whether the drug is having side effects.